The FDA approved carvykti, a new customized, cell-based treatment from Johnson & Johnson, for the treatment of multiple myeloma, Johnson & Johnson said Feb. 28.
Read the full post on Becker's Hospital Review - Healthcare News
FDA approves new CAR-T cell therapy for multiple myeloma
